Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Polypharmacy in schizophrenia

Publikation: Bidrag til tidsskriftReviewForskningpeer review


  1. Drug-related challenges following primary total hip and knee arthroplasty

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. BCPT policy for experimental and clinical studies

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  1. The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Schizophrenia is a severe mental disorder characterized by a heterogeneous symptom profile which comprises a clinical platform for widespread use of polypharmacy even though antipsychotic monotherapy is the recommended treatment regimen. This narrative review provides a summary of the current gap between evidence and practice for use of antipsychotic combination therapy in patients with schizophrenia. Antipsychotic polypharmacy is frequently prescribed instead of following international consensus of clozapine monotherapy in treatment-resistant patients. Antipsychotic-benzodiazepine combination therapy clearly has a role in the treatment of acute agitation whereas there is no evidence to support an effect on core schizophrenia symptoms when chronically prescribed. Antidepressants are typically added to antipsychotic treatment in case of persistent negative symptoms. Available evidence suggests that antidepressants may improve negative symptom control in schizophrenia. Combining an antipsychotic with an antiepileptic is not supported by any firm evidence, but individual mood stabilizers have come out positively in single trials. Generally, the evidence base for polypharmacy in schizophrenia maintenance treatment is sparse but may be warranted in certain clinical situations. Therapeutic benefits and side effects should be carefully monitored and considered to ensure a beneficial risk-benefit ratio if prescribing polypharmacy for specific clinical indications.

TidsskriftBasic & clinical pharmacology & toxicology
Udgave nummer3
Sider (fra-til)183-192
Antal sider10
StatusUdgivet - mar. 2020

Bibliografisk note

© 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.

ID: 59086833